Get the Stockscreener App
19.99
1.22%
0.24
Neurogene Inc stock is traded at $19.99, with a volume of 134.94K.
It is up +1.22% in the last 24 hours and down -8.89% over the past month.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
See More
Previous Close:
$19.75
Open:
$20.1
24h Volume:
134.94K
Relative Volume:
0.77
Market Cap:
$285.30M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-2.54%
1M Performance:
-8.89%
6M Performance:
+15.15%
1Y Performance:
-40.88%
1-Day Range:
$19.65
$20.63
1-Week Range:
$19.06
$21.50
52-Week Range:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Name
Neurogene Inc
Sector
Industry
Phone
(877) 237-5020
Address
535 W 24TH STREET, NEW YORK
Compare NGNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
19.99 | 291.86M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Craig Hallum | Buy |
| May-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Mar-21-24 | Initiated | William Blair | Outperform |
| Jan-08-24 | Initiated | H.C. Wainwright | Buy |
| Jan-05-24 | Initiated | Stifel | Buy |
| Jan-04-24 | Initiated | TD Cowen | Outperform |
View All
Neurogene Inc Stock (NGNE) Latest News
How moving averages guide Neurogene Inc. tradingQuarterly Market Summary & Weekly Stock Breakout Alerts - Newser
Using data models to predict Neurogene Inc. stock movementInsider Selling & Technical Pattern Based Buy Signals - Newser
Published on: 2025-08-20 16:31:54 - thegnnews.com
Quantitative breakdown of Neurogene Inc. recent moveTrade Exit Report & Growth Focused Entry Reports - Newser
Should you hold or exit Neurogene Inc. nowRecession Risk & AI Based Trade Execution Alerts - Newser
Using economic indicators to assess Neurogene Inc. potentialWeekly Trade Review & Expert Verified Stock Movement Alerts - Newser
Has Neurogene Inc. found a price floorJuly 2025 Opening Moves & Weekly Momentum Stock Picks - Newser
Is Neurogene Inc. building a consolidation base2025 Earnings Impact & Weekly High Momentum Picks - Newser
Applying Elliott Wave Theory to Neurogene Inc.Market Activity Recap & Precise Entry and Exit Recommendations - Newser
Visual analytics tools that track Neurogene Inc. performance2025 Support & Resistance & Fast Gain Swing Alerts - Newser
Has Neurogene Inc. formed a bullish divergenceWeekly Profit Summary & Community Verified Watchlist Alerts - Newser
Will Neurogene Inc. bounce back from current supportLayoff News & Reliable Breakout Forecasts - Newser
What MACD signals say about Neurogene Inc.2025 AllTime Highs & Technical Analysis for Trade Confirmation - Newser
Watch for Bullish Crossover in Neurogene Inc.Quarterly Profit Report & Weekly Stock Performance Updates - 선데이타임즈
Ranking Neurogene Inc. among high performing stocks via toolsQuarterly Portfolio Summary & Low Volatility Stock Recommendations - Newser
How to monitor Neurogene Inc. with trend dashboardsWeekly Stock Summary & Community Driven Trade Alerts - Newser
Momentum Indicator Shows Bearish Divergence in Neurogene Inc.Market Performance Summary & Weekly High Return Forecasts - 선데이타임즈
Sentiment analysis tools applied to Neurogene Inc.Market Movement Recap & Real-Time Buy Zone Alerts - Newser
Is Neurogene Inc. reversing from oversold territoryNew Guidance & Safe Entry Momentum Tips - Newser
Wyckoff Accumulation Phase Possible in Neurogene Inc.Weekly Profit Summary & Reliable Price Breakout Alerts - classian.co.kr
What risks could impact Neurogene Inc. stock performance2025 Market Sentiment & Daily Stock Trend Reports - Newser
Can trapped investors hope for a rebound in Neurogene Inc.2025 Winners & Losers & Safe Entry Momentum Tips - Newser
Neurogene Inc. stock trend outlook and recovery path2025 Short Interest & Fast Moving Trade Plans - Newser
How Neurogene Inc. stock performs during market volatilityMarket Trend Review & Low Risk Profit Maximizing Plans - Newser
How to read the order book for Neurogene Inc.July 2025 WrapUp & AI Forecast for Swing Trade Picks - Newser
Neurogene’s Clinical Progress and Financial Resilience Underpin Buy Rating Despite Regulatory Challenges - TipRanks
Q3 Earnings Forecast for Neurogene Issued By Leerink Partnrs - Defense World
What is HC Wainwright’s Estimate for Neurogene Q3 Earnings? - Defense World
Technical Heatmap Flags Neurogene Inc. for Watch2025 Market Outlook & Free High Return Stock Watch Alerts - 선데이타임즈
Pattern Scan Adds Neurogene Inc. to WatchlistWeekly Trade Recap & Free Technical Pattern Based Buy Signals - sundaytimes.kr
Short Term Charts Align With Long Term Uptrend in Neurogene Inc.Market Activity Summary & AI Forecast for Swing Trade Picks - thegnnews.com
Neurogene Inc Stock (NGNE) Financials Data
There is no financial data for Neurogene Inc (NGNE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):